| 영문 | solid tumor | 한글 | 고형종양 |
|---|---|---|---|
| 설명 | 세포로 꽉 찬 종양을 말함. 백혈병 등의 혈액암과 같이 형태를 취하지 않고 액체인 상태의 암과 대조되는 용어로서 단단한 덩어리로 구성된 악성종양이다. 대부분의 종양이 이에 해당한다. 특히 표피조직에서 기원한 종양을 말한다. |
||
| 영문 | ulcerating tumor | 한글 | 궤양성 종양 |
|---|---|---|---|
| 설명 | 종양의 표면에 궤양이 발생하는 것. 대개, 매우 빨리 자라는 종양에서 혈류 공급이 종양세포의 자라는 속도를 감당하지 못해 종양중심부 조직이 괴사에 빠져 궤양을 형성하는 경우가 많다. 육안으로 보면 빨갛고, 열이나며, 지저분해 보인다. |
||
| 영문 | brain tumor | 한글 | 뇌종양 |
|---|---|---|---|
| 설명 | 뇌종양이란 뇌와 뇌조직에서 생긴 종양을 지칭하는 말이다. 그러나 대개 넓은 의미로 사용할 경우에는 머리뼈속의 공간인 두개강속에 생기는 모든 종양을 이르는 말로 사용된다. 뇌종양은 한정된 공간인 두개강에서 발생하므로 종양이 그다지 크지 않아도 정상적인 조직을 압박하게 되고, 두개강내의 압력을 높인다. 이런 특징에 의해서 뇌종양의 증상은 다른 종양과 달리, 종양 그 자체의 증상보다도 두개내압상승과 정상조직의 압박에 의한 증상이 많다. 두개내압(뇌압)의 상승에 의한 증상으로는 두통, 구토등이 있으며, 지속적인 뇌압상승에 의해서 유두부종(papilledema)이 관찰되기도 한다. 그리고 정상적인 뇌조직의 압박과 종양이 생긴 부위의 기능의 결합에 뇌의 그 부분에 해당하는 기능의 상실을 보게된다. |
||
| 영문 | epithelial tumor | 한글 | 상피성종양 |
|---|---|---|---|
| 설명 | 정상 사람의 조직은 체표면을 덮는 역할을 하는 조직과, 주로 발생기의 중배엽에서 분화한 간엽조직에서 유래하는 결합조직, 뼈, 연골, 지방, 근육, 혈관 등의 조직의 두 계통으로 나눌 수 있다. 전자를 상피성 조직, 후자를 비상피성 조직이라 하며 그 각각을 구성하는 세포를 상피성 세포, 비상피세포라 총칭한다. 상피성 세포에서 기원하는 종양이 상피성 종양이며, 근처의 조직으로 침투나 혈류, 림프의 조직을 타고 원거리의 장기로 이동하지 않는 양성종양에는 선종, 유두종 등이 있고 양성과 반대로 근처의 조직으로 침투, 원격장기로 전이하는 악성종양을 모두 통칭하여 암종(carcinoma)이라고 한다. |
||
| 영문 | medullary tumor | 한글 | 수질성 종양 |
|---|---|---|---|
| 설명 | 암의 병리학적인 분류중 하나. 여러 기관의 암에서 나타나는데 주로 갑상샘암이나 유방암에서 보인다. |
||
| VHL | Von Hippel-Lindau Syndrome = Cerebelloretinal Hemangioblastomatosis |
|---|---|
| HLD | hepatolenticular degeneration; herniated lumbar disk; Hippel-Lindau disease; hypersensitivity lung d... |
| HLS | Health Learning System; Hippel-Lindau syndrome |
| VHL | von Hippel-Lindau [syndrome] |
| AFP | Alpha(α) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
| VHL | Van Hippel-Lindau disease |
|---|---|
| VHL | Von Hippel Lindau |
| VHLD | Von Hippel Lindau disease |
| VHL | Von Hippel-Lindau syndrome |
| ATLS | Acute tumor lysis syndrome |
| tumor | 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant. 2. Swelling, one of the cardinal signs of inflammations, morbid enlargement. Origin: L. Tumere = to swell (12 May 1997) |
|---|---|
| tumor marker | <investigation, oncology> A substance in the body that usually indicates the presence of cancer. These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples. Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH). They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids. (18 Jul 2002) |
| tumor necrosis factor | <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin. Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine. Synonym: cachectin. Acronym: TNF (13 Nov 1997) |
| von hippel-lindau disease | <disease> A congenital disease characterised by the development of blood vesse ltumours in the retina of the eye and in the brain, lesions and cysts canalso develop in the spina lcord, pancreas, kidneys, and other organs. (09 Oct 1997) |
| von hippel-lindau syndrome | <radiology> Retinocerebellar angiomatosis, phakomatosis, autosomal dominant (variable penetrance), haemangioblastoma: most frequent cause of death, cerebellar (most common), also medullary and spinal, retinal angiomatosis (45%), renal cell carcinoma: 2nd most common cause of death, pheochromocytoma (17%), cortical renal cysts (75%), cysts in virtually any organ, renal/liver haemangioma/adenoma, pancreatic cystic neoplasms, isleT-cell tumours, paraganglioma (12 Dec 1998) |
| hippel-lindau disease | A syndrome transmitted as an autosomal dominant trait and characterised chiefly by angiomata of the retina and haemangioblastoma of the cerebellum and walls of the fourth ventricle. Ocular complications are often present, as are haemangiomas of the spinal cord, face, and other sites. Symptoms may not be apparent until the third decade in life. (12 Dec 1998) |
| syndrome, von hippel-lindau | The cardinal features of von hippel-lindau (vhl) syndrome are benign blood-vessel tumours that most typically affect the eye and the brain. The eye tumours are termed angiomata and are in the retina. The brain tumours are termed haemangioblastoma and are in the cerebellum. Vhl is complex. There can also be blood-vessel tumours (haemangiomata) in the spinal cord, adrenal glands, liver, and lungs. Pheochromocytoma (a benign tumour of adrenal-like tissue) occurs in some patients. The combination of high blood pressure (hypertension) with angioma may cause bleeding under the skull (subarachnoid haemorrhage). Kidney tumours (like hypernephromas) may be malignant and metastasize. An abnormal elevation of red blood cells (polycythemia) can be due to the haemangioblastoma of the cerebellum or the hypernephroma. Multiple cysts can occur in the pancreas and kidneys. Patients with kidney problems or pancreatic cysts do not have pheochromocytoma, and visa versa. Lab findings in vhl may include high calcium (hypercalcaemia) and low potassium (hypokalaemia) occurring with the pheochromocytoma. Vhl is inherited as an autosomal dominant trait. The gene on one of the non-sex chromosomes is dominant over the normal gene with which it is paired so that one vhl gene is sufficient to cause the vhl syndrome. If a person has vhl, the chance for each of their children to receive the vhl gene is one-half (50%). The vhl gene has been mapped to chromosome 3 (the 3rd volume in the book of life) in region 3p26-p25. The vhl gene has the characteristics of a tumour-suppressor gene. The person with vhl inherits one inactive copy of the vhl gene (a germline mutation) from one of their parents. But the normal gene with which it is paired is still enough to suppress the formation of a tumour. Then, in one cell in the vhl patient's body, another mutation (a somatic mutation) occurs, inactivating the vhl gene. Thus, both copies of the vhl gene are inactivated and a tumour arises in the vhl patient. The syndrome is named for the german ophthalmologist eugen von hippel who described the charcteristic eye blood-vessel tumours in 1904 and the swedish pathologist arvid lindau who recognised the association between the eye tumours and the blood-vessel tumours of the cerebellum and other parts of the central nervous system in 1926-7. (12 Dec 1998) |
| Lindau | Arvid, Swedish pathologist, 1892-1958. See: Lindau's disease, Lindau's tumour, von Hippel-Lindau syndrome. (05 Mar 2000) |
| Lindau's disease | <radiology> Retinocerebellar angiomatosis, phakomatosis, autosomal dominant (variable penetrance), haemangioblastoma: most frequent cause of death, cerebellar (most common), also medullary and spinal, retinal angiomatosis (45%), renal cell carcinoma: 2nd most common cause of death, pheochromocytoma (17%), cortical renal cysts (75%), cysts in virtually any organ, renal/liver haemangioma/adenoma, pancreatic cystic neoplasms, isleT-cell tumours, paraganglioma (12 Dec 1998) |
| Lindau's tumour | <oncology, tumour> A haemangioma, or type of tumour composed of blood vessel or angioblast cells, which occurs in the brain. (09 Oct 1997) |
| lindau-von hippel syndrome | <syndrome> The cardinal features of what is more commonly called von hippel-lindau (vhl) syndrome are benign blood-vessel tumours that most typically affect the eye and the brain. The eye tumours are termed angiomata and are in the retina. The brain tumours are termed haemangioblastoma and are in the cerebellum. Vhl is complex. There can also be blood-vessel tumours (haemangiomata) in the spinal cord, adrenal glands, liver, and lungs. Pheochromocytoma (a benign tumour of adrenal-like tissue) occurs in some patients. The combination of high blood pressure (hypertension) with angioma may cause bleeding under the skull (subarachnoid haemorrhage). Kidney tumours (like hypernephromas) may be malignant and metastasize. An abnormal elevation of red blood cells (polycythemia) can be due to the haemangioblastoma of the cerebellum or the hypernephroma. Multiple cysts can occur in the pancreas and kidneys. Patients with kidney problems or pancreatic cysts do not have pheochromocytoma, and visa versa. Lab findings in vhl may include high calcium (hypercalcaemia) and low potassium (hypokalaemia) occurring with the pheochromocytoma. Vhl is inherited as an autosomal dominant trait. The gene on one of the non-sex chromosomes is dominant over the normal gene with which it is paired so that one vhl gene is sufficient to cause the vhl syndrome. If a person has vhl, the chance for each of their children to receive the vhl gene is one-half (50%). The vhl gene has been mapped to chromosome 3 (the 3rd volume in the book of life) in region 3p26-p25. The vhl gene has the characteristics of a tumour-suppressor gene. The person with vhl inherits one inactive copy of the vhl gene (a germline mutation) from one of their parents. But the normal gene with which it is paired is still enough to suppress the formation of a tumour. Then, in one cell in the vhl patient's body, another mutation (a somatic mutation) occurs, inactivating the other vhl gene. Thus, both copies of the vhl gene are inactivated and a tumour arises in the vhl patient. The syndrome is named for the german ophthalmologist eugen von hippel who described the charcteristic eye blood-vessel tumours in 1904 and the swedish pathologist arvid lindau who recognised the association between the eye tumours and the blood-vessel tumours of the cerebellum and other parts of the central nervous system in 1926-7. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|